Table 1.
Patient characteristics
| Characteristic | PFS <16 months | PFS >16 months |
|---|---|---|
| Patients (n) | 39 | 16 |
| Age—year | ||
| Median | 59* | 48* |
| Range | 18–75 | 22–66 |
| Gender—no (%) | ||
| Female | 12 (31) | 4 (25) |
| Male | 27 (69) | 12 (75) |
| Histology—no (%) | ||
| Glioblastoma | 39 (100) | 16 (100) |
| Tumor location—no (%) | ||
| Left | 14 (36) | 5 (31) |
| Right | 20 (51) | 11 (69) |
| Multifocal | 5 (13) | – |
| WHO performance | ||
| 0 | 22 (56 %) | 8 (50 %) |
| 1 | 15 (38 %) | 6 (38 %) |
| 2 | 1 (3 %) | |
| Missing | 1 (3 %) | 2 (13 %) |
| Extent of surgery | ||
| Biopsy | 4 (10 %) | – |
| Debulking | ||
| Partial | 15 (38 %) | 10 (63 %) |
| Maximal | 9 (23 %) | 6 (38 %) |
| Unknown | 11 (28 %) | |
| Time from diagnosis to radiotherapy—weeks | ||
| Median | 4.0 | 4.1 |
| Range | 1.7–57.3 | 3.1–5.7 |
| Radiotherapy—dose | ||
| 42 Gy | 2 (5 %) | |
| 75 Gy | 37 (95 %) | 16 (100 %) |
| TMZ—dose | ||
| 0 mg/m2 | 2 (5 %) | – |
| 75 mg/m2 | 37 (95 %) | 16 (100 %) |
| Dose reductions (number of pat) | 4 (10 %) | 2 (13 %) |
| Average adjuvant cycles—no | 4.2 | 5 |
| Corticosteroid therapy | ||
| Yes | 19 (49 %)** | 1 (6 %)** |
| No | 20 (51 %)** | 15 (94 %)** |
| Anti-epileptic therapy | ||
| Yes | 18 (46 %) | 9 (56 %) |
| No | 20 (51 %) | 7 (44 %) |
| Missing | 1 (3 %) | – |
*p = 0.02 and **p = 0.002